Belite Bio (BLTE) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Q1 2026 earnings are due after the close on May 12, with analysts forecasting a loss of ($0.60) per share and an investor call scheduled for May 13; Belite previously beat estimates in its last quarter, reporting ($0.38) vs. a ($0.56) consensus.
• Insiders have recently sold shares—CFO Hao‑Yuan Chuang sold 6,200 shares on April 9 and insiders disposed of 24,500 shares (~$4.29M) in the past 90 days—though corporate insiders still own 13.29% of the company.
• The stock traded at about $158.39 midday with a market cap of $6.33 billion, and analysts maintain a consensus rating of Moderate Buy with an average target price of $202.33.

Belite Bio (NASDAQ:BLTE - Get Free Report) is anticipated to issue its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.60) per share for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

Belite Bio (NASDAQ:BLTE - Get Free Report) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.18. On average, analysts expect Belite Bio to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Belite Bio Stock Performance

Shares of NASDAQ:BLTE traded up $3.88 during midday trading on Tuesday, reaching $158.39. The company had a trading volume of 19,351 shares, compared to its average volume of 185,602. Belite Bio has a 1-year low of $56.10 and a 1-year high of $200.00. The firm has a market cap of $6.33 billion, a price-to-earnings ratio of -68.86 and a beta of -1.19. The company has a fifty day simple moving average of $167.98 and a two-hundred day simple moving average of $151.52.

Insider Buying and Selling

In related news, CFO Hao-Yuan Chuang sold 6,200 shares of the stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $181.50, for a total value of $1,125,300.00. Following the completion of the sale, the chief financial officer directly owned 93,800 shares of the company's stock, valued at approximately $17,024,700. This represents a 6.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Wan-Shan Chen sold 1,100 shares of the stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $180.43, for a total value of $198,473.00. Following the completion of the sale, the director directly owned 9,096 shares of the company's stock, valued at approximately $1,641,191.28. This represents a 10.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 24,500 shares of company stock valued at $4,290,813. Corporate insiders own 13.29% of the company's stock.

Institutional Investors Weigh In On Belite Bio

Hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd lifted its stake in Belite Bio by 28,200.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company's stock worth $45,000 after acquiring an additional 282 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in Belite Bio in the 4th quarter worth about $108,000. Bank of America Corp DE lifted its stake in Belite Bio by 28.1% in the 3rd quarter. Bank of America Corp DE now owns 1,171 shares of the company's stock worth $87,000 after acquiring an additional 257 shares in the last quarter. Brooklyn Investment Group purchased a new stake in Belite Bio in the 4th quarter worth about $287,000. Finally, Royal Bank of Canada purchased a new stake in shares of Belite Bio during the 4th quarter worth about $334,000. 0.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on BLTE. Weiss Ratings reiterated a "sell (d-)" rating on shares of Belite Bio in a research report on Tuesday, April 7th. Benchmark reiterated a "buy" rating on shares of Belite Bio in a research report on Tuesday, March 3rd. Mizuho set a $223.00 price target on Belite Bio in a research report on Thursday, February 19th. Needham & Company LLC set a $217.00 price target on Belite Bio in a research report on Tuesday, March 3rd. Finally, Wall Street Zen upgraded Belite Bio from a "sell" rating to a "hold" rating in a research report on Saturday, April 4th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $202.33.

About Belite Bio

Belite Bio, Inc NASDAQ: BLTE is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.